Omeros (OMER) Reaches New 12-Month High at $27.00

Shares of Omeros Co. (NASDAQ:OMER) hit a new 52-week high on Tuesday . The company traded as high as $27.00 and last traded at $26.55, with a volume of 16235 shares trading hands. The stock had previously closed at $26.28.

OMER has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Omeros from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Saturday, July 28th. HC Wainwright set a $34.00 price target on shares of Omeros and gave the company a “buy” rating in a research report on Tuesday, July 24th. Seaport Global Securities began coverage on shares of Omeros in a report on Thursday, July 12th. They set a “buy” rating and a $30.00 target price on the stock. ValuEngine upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Friday, July 6th. Finally, Maxim Group raised their target price on shares of Omeros from $25.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and two have given a strong buy rating to the company. Omeros currently has an average rating of “Buy” and an average target price of $27.56.

The company has a current ratio of 3.95, a quick ratio of 3.94 and a debt-to-equity ratio of -2.31. The firm has a market capitalization of $1.22 billion, a P/E ratio of -33.92 and a beta of 3.84.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.84 million. The business’s revenue for the quarter was down 90.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) EPS. equities research analysts forecast that Omeros Co. will post -2.48 EPS for the current year.

In other news, VP Marcia S. Kelbon sold 4,277 shares of the firm’s stock in a transaction that occurred on Thursday, July 12th. The shares were sold at an average price of $21.48, for a total transaction of $91,869.96. Following the completion of the transaction, the vice president now directly owns 188,922 shares of the company’s stock, valued at approximately $4,058,044.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Marcia S. Kelbon sold 40,723 shares of the firm’s stock in a transaction that occurred on Friday, July 27th. The stock was sold at an average price of $21.56, for a total transaction of $877,987.88. Following the transaction, the vice president now directly owns 219,645 shares of the company’s stock, valued at $4,735,546.20. The disclosure for this sale can be found here. Insiders have sold a total of 52,529 shares of company stock worth $1,163,730 over the last 90 days. Corporate insiders own 12.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of OMER. Swiss National Bank grew its stake in shares of Omeros by 5.3% in the first quarter. Swiss National Bank now owns 79,100 shares of the biopharmaceutical company’s stock valued at $884,000 after buying an additional 4,000 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Omeros by 3.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 222,678 shares of the biopharmaceutical company’s stock worth $2,488,000 after purchasing an additional 6,800 shares during the period. BlackRock Inc. boosted its position in Omeros by 0.9% during the first quarter. BlackRock Inc. now owns 3,965,410 shares of the biopharmaceutical company’s stock worth $44,294,000 after purchasing an additional 34,832 shares during the period. Russell Investments Group Ltd. boosted its position in Omeros by 30.8% during the first quarter. Russell Investments Group Ltd. now owns 29,884 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 7,037 shares during the period. Finally, Stifel Financial Corp boosted its position in Omeros by 1.9% during the first quarter. Stifel Financial Corp now owns 348,726 shares of the biopharmaceutical company’s stock worth $3,902,000 after purchasing an additional 6,534 shares during the period. 48.11% of the stock is owned by institutional investors.

Omeros Company Profile (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

See Also: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply